Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI

Real-world use of bezlotoxumab and fecal microbiota transplantation for the treatment of Clostridioides difficile infection

(2023) Sofía de la Villa et al.   Open Forum Infectious Diseases

A Tapered-Pulsed Fidaxomicin Regimen following Treatment in Patients with Multiple Clostridioides difficile Infection Recurrences

(2021) Andrew M Skinner et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults

(2021) Stuart Johnson et al.   CLINICAL INFECTIOUS DISEASES

Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study

(2020) Richard L Hengel et al.   Open Forum Infectious Diseases

Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection

(2020) Rosa Escudero-Sánchez et al.   Journal of Clinical Medicine

Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland

(2019) Jarmo Oksi et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence

(2018) Dale N Gerding et al.   CLINICAL INFECTIOUS DISEASES

Bezlotoxumab

(2018) Stuart Johnson et al.   CLINICAL INFECTIOUS DISEASES

Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection

(2018) Thomas Birch et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

(2017) Mark H. Wilcox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bezlotoxumab: First Global Approval

(2016) Anthony Markham   DRUGS

Toxin-Mediated Paracellular Transport of Antitoxin Antibodies Facilitates Protection against Clostridium difficile Infection

(2014) Z. Zhang et al.   INFECTION AND IMMUNITY

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin

(2012) O. A. Cornely et al.   CLINICAL INFECTIOUS DISEASES